Mergers & Acquisitions ·
Theravance Biopharma, Inc. entered into a merger agreement with Zymeworks Inc. to be acquired for $17.00 per ordinary…
TBPHTheravance Biopharma, Inc.
Theravance Biopharma, Inc. entered into a merger agreement with Zymeworks Inc. to be acquired for $17.00 per ordinary share in cash and one contingent value right (CVR) per share. The transaction is expected to close in the second half of 2026 and is subject to shareholder approval and customary closing conditions. Theravance Biopharma, Inc. is a biopharmaceutical company focused on respiratory and gastrointestinal diseases.